[¹⁸F] Clofarabine for PET Imaging of Hepatocellular Carcinoma.

ABSTRACT: Clinical diagnosis of hepatocellular carcinoma (HCC) relies heavily on radiological imaging. However, information pertaining to liver cancer treatment such as the proliferation status is lacking. Imaging tumor proliferation can be valuable in patient management. This study investigated ¹⁸F-labeled clofarabine ([¹⁸F]CFA) targeting deoxycytidine kinase (dCK) for PET imaging of dCK-dependent proliferation in HCC. Since clinical PET scans showed a high liver background uptake of [¹⁸F]CFA, the aim of this study was to reduce this liver background uptake. A clinically relevant animal model of spontaneously developed HCC in the woodchucks was used for imaging experiments. Several modifiers were tested and compared with the baseline PET scan: Forodesine, probenecid

SUBMITTER: Sergeeva O 

PROVIDER: S-EPMC6896045 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature